FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...